{"nctId":"NCT01725308","briefTitle":"A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes","startDateStruct":{"date":"2012-02-07","type":"ACTUAL"},"conditions":["Bipolar Disorder"],"count":431,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"FK949E 150 mg","type":"EXPERIMENTAL","interventionNames":["Drug: FK949E"]},{"label":"FK949E 300 mg","type":"EXPERIMENTAL","interventionNames":["Drug: FK949E"]},{"label":"Placebo / FK949E","type":"EXPERIMENTAL","interventionNames":["Drug: FK949E","Drug: Placebo"]},{"label":"FK949E 150 mg / FK949E","type":"EXPERIMENTAL","interventionNames":["Drug: FK949E"]},{"label":"FK949E 300 mg / FK949E","type":"EXPERIMENTAL","interventionNames":["Drug: FK949E"]}],"interventions":[{"name":"FK949E","otherNames":["quetiapine"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of bipolar I or II disorder as specified in the Diagnostic and Statistical Manual of Mental Disorders Ver. 4 Text Revision (DSM-IV-TR,) with a major depressive episode\n* The Hamilton Depression Rating Scale (HAM-D17) total score of 20 points or more and HAM-D17 depressed mood score of 2 points or more\n* Able to participate in the study with understanding of and compliance with subject requirements during the study in the investigator's or subinvestigator's opinion\n\nExclusion Criteria:\n\n* Concurrent or previous history of DSM-IV-TR Axis I disorders, except bipolar disorder, within the last 6 months before informed consent\n* Concurrence of DSM-IV-TR Axis II disorder that is considered to greatly affect patient's current mental status\n* The Young Mania Rating Scale (YMRS) total score of 13 points or more\n* Nine or more mood episodes within the last 12 months before informed consent\n* Lack of response to at least 6-week treatment with at least 2 antidepressants for the current major depressive episode in the investigator's or subinvestigator's opinion\n* History of abuse or dependence of alcohol or substances other than caffeine and nicotine\n* Treatment with a depot antipsychotic within the last 42 days before primary registration\n* Unable to stop taking mood stabilizers (lithium carbonate and/or sodium valproate), lamotrigine, antipsychotics, or antidepressants from 7 days before secondary registration\n* Unable to stop taking antiepileptics (except lamotrigine and sodium valproate), antianxiety agents, hypnotics, sedatives, psychostimulants, antiparkinsonian agents, cerebral ameliorators, antidementia agents, or anorectics, except those specified as conditionally-allowed concomitant drugs, after primary registration\n* Electroconvulsive therapy within the last 76 days before primary registration\n* The current major depressive episode persisting for more than 12 months or less than 4 weeks before informed consent\n* A possible need of psychotherapy during the study period (unless the therapy has been commenced at least 76 days before primary registration and been maintained on a fixed level at fixed frequency)\n* Documented or suspected conditions such as renal failure, hepatic failure, serious cardiac disease, hepatitis B, hepatitis C, or acquired immunodeficiency syndrome (AIDS) (or to be a carrier of hepatitis B, hepatitis C, or AIDS)\n* Concurrence of malignancy or history of cured malignancy within 5 years\n* Concurrence of uncontrolled hypertension (defined as a systolic blood pressure of 180 mmHg or more, or a diastolic blood pressure of 110 mmHg or more at primary registration) or unstable angina that may worsen with the study or may affect the study results based on the clinical judgment of the investigator or sub-investigator\n* Concurrence of hypotension (defined as a systolic blood pressure of less than 100 mmHg at primary registration) or orthostatic hypotension\n* History of transient, idiopathic orthostatic hypotension, with or without pre-syncope symptoms or syncope, or a current condition susceptible to transient hypotension, such as dehydration and decreased blood volume\n* Concurrent or previous history of cerebrovascular disease or transient ischemic attack (TIA)\n* Abnormal laboratory or electrocardiographic findings considered clinically significant in the investigator's or subinvestigator's opinion (in reference to grade 3 of the Adverse Drug Reactions Severity Grading Criteria \\[Notification No. 80 of the Safety Division, Pharmaceutical Affairs Bureau, Ministry of Health and Welfare dated 29 June 1992\\])\n* Participation in another clinical study or post-marketing study within the last 12 weeks before informed consent\n* History of quetiapine therapy during the current major depressive episode\n* Pregnant or lactating women","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to End of Treatment Period I in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","description":"The MADRS is a 10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.1","spread":"10.9"},{"groupId":"OG001","value":"-14.4","spread":"11.4"},{"groupId":"OG002","value":"-12.6","spread":"11.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in MADRS Total Score (Treatment Period I)","description":"The MADRS is a 10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.5","spread":"5.4"},{"groupId":"OG001","value":"-6.4","spread":"8.1"},{"groupId":"OG002","value":"-5.1","spread":"6.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.1","spread":"7.0"},{"groupId":"OG001","value":"-10.0","spread":"8.9"},{"groupId":"OG002","value":"-8.3","spread":"8.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.1","spread":"8.8"},{"groupId":"OG001","value":"-11.6","spread":"9.9"},{"groupId":"OG002","value":"-9.9","spread":"9.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.5","spread":"9.1"},{"groupId":"OG001","value":"-12.5","spread":"10.8"},{"groupId":"OG002","value":"-11.8","spread":"9.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.2","spread":"10.1"},{"groupId":"OG001","value":"-14.5","spread":"11.0"},{"groupId":"OG002","value":"-12.2","spread":"10.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.1","spread":"10.9"},{"groupId":"OG001","value":"-14.4","spread":"11.4"},{"groupId":"OG002","value":"-12.6","spread":"11.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in MADRS Total Score (Combined Treatment Period I and II)","description":"The MADRS is a10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms. Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"-6.4","spread":"8.1"},{"groupId":"OG002","value":"-5.1","spread":"6.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-10.0","spread":"8.9"},{"groupId":"OG002","value":"-8.5","spread":"8.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-12.0","spread":"10.1"},{"groupId":"OG002","value":"-10.6","spread":"9.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-13.1","spread":"11.0"},{"groupId":"OG002","value":"-13.2","spread":"9.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-15.6","spread":"11.2"},{"groupId":"OG002","value":"-13.8","spread":"10.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-15.8","spread":"11.5"},{"groupId":"OG002","value":"-14.8","spread":"10.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-16.3","spread":"11.6"},{"groupId":"OG002","value":"-15.9","spread":"10.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-16.4","spread":"12.1"},{"groupId":"OG002","value":"-16.0","spread":"10.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"5.8"},{"groupId":"OG001","value":"-18.1","spread":"10.4"},{"groupId":"OG002","value":"-13.3","spread":"10.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"7.0"},{"groupId":"OG001","value":"-17.0","spread":"10.7"},{"groupId":"OG002","value":"-16.4","spread":"10.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.3","spread":"7.7"},{"groupId":"OG001","value":"-17.1","spread":"10.3"},{"groupId":"OG002","value":"-17.2","spread":"10.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.8","spread":"8.0"},{"groupId":"OG001","value":"-17.3","spread":"11.5"},{"groupId":"OG002","value":"-19.0","spread":"9.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.8","spread":"8.3"},{"groupId":"OG001","value":"-18.7","spread":"10.6"},{"groupId":"OG002","value":"-18.2","spread":"9.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.1","spread":"8.5"},{"groupId":"OG001","value":"-21.4","spread":"10.5"},{"groupId":"OG002","value":"-18.4","spread":"10.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.0","spread":"8.6"},{"groupId":"OG001","value":"-22.9","spread":"8.5"},{"groupId":"OG002","value":"-19.4","spread":"10.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":"10.2"},{"groupId":"OG001","value":"-22.3","spread":"9.6"},{"groupId":"OG002","value":"-19.4","spread":"10.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.5","spread":"9.4"},{"groupId":"OG001","value":"-23.1","spread":"10.4"},{"groupId":"OG002","value":"-19.4","spread":"10.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.2","spread":"9.8"},{"groupId":"OG001","value":"-23.3","spread":"9.7"},{"groupId":"OG002","value":"-19.8","spread":"10.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.1","spread":"10.0"},{"groupId":"OG001","value":"-23.4","spread":"10.2"},{"groupId":"OG002","value":"-20.7","spread":"9.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.6","spread":"10.0"},{"groupId":"OG001","value":"-24.1","spread":"10.2"},{"groupId":"OG002","value":"-20.9","spread":"10.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.8","spread":"10.7"},{"groupId":"OG001","value":"-24.4","spread":"10.1"},{"groupId":"OG002","value":"-22.1","spread":"9.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":"10.4"},{"groupId":"OG001","value":"-16.0","spread":"13.3"},{"groupId":"OG002","value":"-15.2","spread":"12.2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With MADRS Response (Treatment Period I)","description":"A MADRS response was defined as a decrease in MADRS total score of 50% or more from baseline. The MADRS is a10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"79","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With MADRS Response (Combined Treatment Period I and II)","description":"A MADRS response was defined as a decrease in MADRS total score of 50% or more from baseline. The MADRS is a 10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms. Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"89","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With MADRS Remission (Treatment Period I)","description":"MADRS remission was defined as MADRS total score of 12 or less. The MADRS is a 10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"68","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With MADRS Remission (Combined Treatment Period I and II)","description":"MADRS remission was defined as MADRS total score of 12 or less. The MADRS is a 10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms. Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"82","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hamilton Depression Rating Scale (HAM-D17) Total Score (Treatment Period I)","description":"The HAM-D17 is a clinician-rated 17-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 52, where a higher score indicates a greater depressive state.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"4.2"},{"groupId":"OG001","value":"-5.9","spread":"5.1"},{"groupId":"OG002","value":"-4.5","spread":"4.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.1","spread":"5.4"},{"groupId":"OG001","value":"-8.7","spread":"5.8"},{"groupId":"OG002","value":"-7.0","spread":"6.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":"6.5"},{"groupId":"OG001","value":"-10.0","spread":"6.2"},{"groupId":"OG002","value":"-7.9","spread":"6.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.3","spread":"6.7"},{"groupId":"OG001","value":"-10.9","spread":"6.6"},{"groupId":"OG002","value":"-9.2","spread":"6.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.7","spread":"7.3"},{"groupId":"OG001","value":"-11.9","spread":"7.1"},{"groupId":"OG002","value":"-9.6","spread":"7.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.4","spread":"7.6"},{"groupId":"OG001","value":"-11.9","spread":"7.4"},{"groupId":"OG002","value":"-10.1","spread":"7.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HAM-D17 (Combined Treatment Period I and II)","description":"The HAM-D17 is a clinician-rated 17-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 52, where a higher score indicates a greater depressive state. Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"-5.9","spread":"5.1"},{"groupId":"OG002","value":"-4.5","spread":"4.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-8.8","spread":"5.8"},{"groupId":"OG002","value":"-7.1","spread":"5.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-10.3","spread":"6.0"},{"groupId":"OG002","value":"-8.4","spread":"6.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-11.4","spread":"6.5"},{"groupId":"OG002","value":"-9.9","spread":"6.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-12.7","spread":"7.0"},{"groupId":"OG002","value":"-10.7","spread":"6.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-13.0","spread":"7.1"},{"groupId":"OG002","value":"-11.6","spread":"7.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-13.1","spread":"7.8"},{"groupId":"OG002","value":"-12.4","spread":"7.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-13.7","spread":"7.5"},{"groupId":"OG002","value":"-12.6","spread":"6.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"4.7"},{"groupId":"OG001","value":"-13.9","spread":"7.5"},{"groupId":"OG002","value":"-12.8","spread":"7.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"5.2"},{"groupId":"OG001","value":"-13.7","spread":"7.1"},{"groupId":"OG002","value":"-13.4","spread":"6.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"6.0"},{"groupId":"OG001","value":"-14.6","spread":"7.3"},{"groupId":"OG002","value":"-13.8","spread":"6.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"6.0"},{"groupId":"OG001","value":"-16.7","spread":"6.4"},{"groupId":"OG002","value":"-14.3","spread":"7.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.9","spread":"6.4"},{"groupId":"OG001","value":"-17.1","spread":"6.9"},{"groupId":"OG002","value":"-14.6","spread":"6.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.7","spread":"7.0"},{"groupId":"OG001","value":"-17.0","spread":"7.6"},{"groupId":"OG002","value":"-15.1","spread":"6.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.6","spread":"7.1"},{"groupId":"OG001","value":"-17.8","spread":"7.9"},{"groupId":"OG002","value":"-16.2","spread":"6.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":"6.6"},{"groupId":"OG001","value":"-12.9","spread":"8.7"},{"groupId":"OG002","value":"-11.6","spread":"8.3"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HAM-D17 Response (Treatment Period I)","description":"A HAM-D17 response was defined as a decrease in HAM-D17 total score of 50% or more from baseline. The HAM-D17 is a clinician-rated 17-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 52, where a higher score indicates a greater depressive state.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"78","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HAM-D17 Response (Combined Treatment Period I and II)","description":"A HAM-D17 response was defined as a decrease in HAM-D17 total score of 50% or more from baseline. The HAM-D17 is a clinician-rated 17-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 52, where a higher score indicates a greater depressive state. Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"43","spread":null},{"groupId":"OG002","value":"95","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Global Impression-Bipolar Disorder-Severity (CGI-BP-S): Mania (Treatment Period I)","description":"The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from 1 (not ill) to 7 (very severely ill).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.2"},{"groupId":"OG001","value":"0.0","spread":"0.2"},{"groupId":"OG002","value":"0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.2"},{"groupId":"OG001","value":"-0.0","spread":"0.2"},{"groupId":"OG002","value":"0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.2"},{"groupId":"OG001","value":"-0.0","spread":"0.2"},{"groupId":"OG002","value":"0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.2"},{"groupId":"OG001","value":"-0.0","spread":"0.4"},{"groupId":"OG002","value":"0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.3"},{"groupId":"OG001","value":"-0.1","spread":"0.2"},{"groupId":"OG002","value":"0.0","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.3"},{"groupId":"OG001","value":"-0.1","spread":"0.4"},{"groupId":"OG002","value":"0.0","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CGI-BP-S: Mania (Combined Treatment Period I and II)","description":"The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from 1 (not ill) to 7 (very severely ill). Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"0.2"},{"groupId":"OG002","value":"0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"0.2"},{"groupId":"OG002","value":"-0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-0.0","spread":"0.2"},{"groupId":"OG002","value":"0.0","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"0.4"},{"groupId":"OG002","value":"0.0","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-0.0","spread":"0.2"},{"groupId":"OG002","value":"0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-0.0","spread":"0.4"},{"groupId":"OG002","value":"-0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-0.0","spread":"0.3"},{"groupId":"OG002","value":"0.0","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"0.1"},{"groupId":"OG002","value":"-0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.3"},{"groupId":"OG001","value":"-0.1","spread":"0.2"},{"groupId":"OG002","value":"-0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.3"},{"groupId":"OG001","value":"-0.1","spread":"0.2"},{"groupId":"OG002","value":"-0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.3"},{"groupId":"OG001","value":"-0.1","spread":"0.2"},{"groupId":"OG002","value":"-0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.3"},{"groupId":"OG001","value":"-0.1","spread":"0.2"},{"groupId":"OG002","value":"-0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.2"},{"groupId":"OG001","value":"-0.0","spread":"0.3"},{"groupId":"OG002","value":"0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.2"},{"groupId":"OG001","value":"-0.0","spread":"0.3"},{"groupId":"OG002","value":"0.0","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.2"},{"groupId":"OG001","value":"0.0","spread":"0.3"},{"groupId":"OG002","value":"0.0","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.2"},{"groupId":"OG001","value":"-0.0","spread":"0.3"},{"groupId":"OG002","value":"-0.0","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.2"},{"groupId":"OG001","value":"0.0","spread":"0.3"},{"groupId":"OG002","value":"0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.2"},{"groupId":"OG001","value":"-0.0","spread":"0.2"},{"groupId":"OG002","value":"-0.0","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.2"},{"groupId":"OG001","value":"-0.0","spread":"0.2"},{"groupId":"OG002","value":"0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.2"},{"groupId":"OG001","value":"-0.0","spread":"0.2"},{"groupId":"OG002","value":"-0.0","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.3"},{"groupId":"OG001","value":"-0.1","spread":"0.3"},{"groupId":"OG002","value":"0.1","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CGI-BP-S: Depression (Treatment Period I)","description":"The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician with the scale from 1 (not ill) to 7 (very severely ill).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.7"},{"groupId":"OG001","value":"-0.5","spread":"0.8"},{"groupId":"OG002","value":"-0.4","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.9"},{"groupId":"OG001","value":"-0.8","spread":"1.0"},{"groupId":"OG002","value":"-0.7","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"1.1"},{"groupId":"OG001","value":"-1.0","spread":"1.1"},{"groupId":"OG002","value":"-0.9","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.1"},{"groupId":"OG001","value":"-1.2","spread":"1.2"},{"groupId":"OG002","value":"-1.1","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.2"},{"groupId":"OG001","value":"-1.3","spread":"1.2"},{"groupId":"OG002","value":"-1.1","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"1.4"},{"groupId":"OG001","value":"-1.4","spread":"1.3"},{"groupId":"OG002","value":"-1.2","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CGI-BP-S: Depression (Combined Treatment Period I and II)","description":"The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from 1 (not ill) to 7 (very severely ill). Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"-0.5","spread":"0.8"},{"groupId":"OG002","value":"-0.4","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-0.8","spread":"1.1"},{"groupId":"OG002","value":"-0.7","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-1.0","spread":"1.2"},{"groupId":"OG002","value":"-1.0","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-1.2","spread":"1.2"},{"groupId":"OG002","value":"-1.2","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-1.4","spread":"1.2"},{"groupId":"OG002","value":"-1.3","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-1.5","spread":"1.3"},{"groupId":"OG002","value":"-1.5","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-1.5","spread":"1.4"},{"groupId":"OG002","value":"-1.6","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-1.5","spread":"1.4"},{"groupId":"OG002","value":"-1.7","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.7"},{"groupId":"OG001","value":"-1.5","spread":"1.4"},{"groupId":"OG002","value":"-1.7","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.8"},{"groupId":"OG001","value":"-1.7","spread":"1.3"},{"groupId":"OG002","value":"-1.7","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.9"},{"groupId":"OG001","value":"-1.7","spread":"1.4"},{"groupId":"OG002","value":"-2.0","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"1.0"},{"groupId":"OG001","value":"-1.8","spread":"1.4"},{"groupId":"OG002","value":"-1.9","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.1"},{"groupId":"OG001","value":"-2.1","spread":"1.4"},{"groupId":"OG002","value":"-2.0","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.2"},{"groupId":"OG001","value":"-2.4","spread":"1.2"},{"groupId":"OG002","value":"-2.0","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.3"},{"groupId":"OG001","value":"-2.4","spread":"1.4"},{"groupId":"OG002","value":"-2.1","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.2"},{"groupId":"OG001","value":"-2.6","spread":"1.4"},{"groupId":"OG002","value":"-2.0","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.3"},{"groupId":"OG001","value":"-2.5","spread":"1.3"},{"groupId":"OG002","value":"-2.1","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.3"},{"groupId":"OG001","value":"-2.3","spread":"1.4"},{"groupId":"OG002","value":"-2.2","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.3"},{"groupId":"OG001","value":"-2.5","spread":"1.3"},{"groupId":"OG002","value":"-2.3","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.4"},{"groupId":"OG001","value":"-2.7","spread":"1.3"},{"groupId":"OG002","value":"-2.4","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.4"},{"groupId":"OG001","value":"-1.8","spread":"1.6"},{"groupId":"OG002","value":"-1.6","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CGI-BP-S: Overall Bipolar Illness (Treatment Period I)","description":"The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician with the scale from 1 (not ill) to 7 (very severely ill).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.7"},{"groupId":"OG001","value":"-0.4","spread":"0.8"},{"groupId":"OG002","value":"-0.4","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.9"},{"groupId":"OG001","value":"-0.7","spread":"1.0"},{"groupId":"OG002","value":"-0.7","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"1.0"},{"groupId":"OG001","value":"-0.9","spread":"1.1"},{"groupId":"OG002","value":"-0.9","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.1"},{"groupId":"OG001","value":"-1.1","spread":"1.1"},{"groupId":"OG002","value":"-1.1","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.2"},{"groupId":"OG001","value":"-1.2","spread":"1.2"},{"groupId":"OG002","value":"-1.1","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"1.3"},{"groupId":"OG001","value":"-1.4","spread":"1.3"},{"groupId":"OG002","value":"-1.2","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CGI-BP-S: Overall Bipolar Illness (Combined Treatment Period I and II)","description":"The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from 1 (not ill) to 7 (very severely ill). Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"-0.4","spread":"0.8"},{"groupId":"OG002","value":"-0.4","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-0.7","spread":"1.0"},{"groupId":"OG002","value":"-0.7","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-0.9","spread":"1.1"},{"groupId":"OG002","value":"-1.0","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-1.1","spread":"1.2"},{"groupId":"OG002","value":"-1.2","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-1.3","spread":"1.2"},{"groupId":"OG002","value":"-1.3","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-1.4","spread":"1.3"},{"groupId":"OG002","value":"-1.5","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-1.4","spread":"1.4"},{"groupId":"OG002","value":"-1.6","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-1.4","spread":"1.5"},{"groupId":"OG002","value":"-1.7","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.7"},{"groupId":"OG001","value":"-1.4","spread":"1.4"},{"groupId":"OG002","value":"-1.6","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.8"},{"groupId":"OG001","value":"-1.6","spread":"1.3"},{"groupId":"OG002","value":"-1.7","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.9"},{"groupId":"OG001","value":"-1.6","spread":"1.4"},{"groupId":"OG002","value":"-1.9","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.0"},{"groupId":"OG001","value":"-1.7","spread":"1.4"},{"groupId":"OG002","value":"-1.9","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.0"},{"groupId":"OG001","value":"-2.0","spread":"1.4"},{"groupId":"OG002","value":"-1.9","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.1"},{"groupId":"OG001","value":"-2.2","spread":"1.3"},{"groupId":"OG002","value":"-1.9","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.3"},{"groupId":"OG001","value":"-2.2","spread":"1.4"},{"groupId":"OG002","value":"-2.0","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.2"},{"groupId":"OG001","value":"-2.4","spread":"1.5"},{"groupId":"OG002","value":"-2.0","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"1.3"},{"groupId":"OG001","value":"-2.3","spread":"1.3"},{"groupId":"OG002","value":"-2.1","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"1.3"},{"groupId":"OG001","value":"-2.2","spread":"1.5"},{"groupId":"OG002","value":"-2.2","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.2"},{"groupId":"OG001","value":"-2.4","spread":"1.5"},{"groupId":"OG002","value":"-2.3","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"1.3"},{"groupId":"OG001","value":"-2.6","spread":"1.4"},{"groupId":"OG002","value":"-2.4","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.3"},{"groupId":"OG001","value":"-1.7","spread":"1.6"},{"groupId":"OG002","value":"-1.5","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression-Bipolar Disorder-Change (CGI-BP-C): Mania (Treatment Period I)","description":"The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"0.3"},{"groupId":"OG001","value":"4.0","spread":"0.2"},{"groupId":"OG002","value":"4.0","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"0.2"},{"groupId":"OG001","value":"4.0","spread":"0.2"},{"groupId":"OG002","value":"4.0","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"0.2"},{"groupId":"OG001","value":"4.0","spread":"0.2"},{"groupId":"OG002","value":"4.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"0.3"},{"groupId":"OG001","value":"4.0","spread":"0.4"},{"groupId":"OG002","value":"4.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"0.3"},{"groupId":"OG001","value":"3.9","spread":"0.2"},{"groupId":"OG002","value":"4.0","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"0.3"},{"groupId":"OG001","value":"3.9","spread":"0.3"},{"groupId":"OG002","value":"4.0","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"CGI-BP-C: Mania (Combined Treatment Period I and II)","description":"The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score. Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"4.0","spread":"0.2"},{"groupId":"OG002","value":"4.0","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"4.0","spread":"0.2"},{"groupId":"OG002","value":"4.0","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"4.0","spread":"0.2"},{"groupId":"OG002","value":"4.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"4.0","spread":"0.3"},{"groupId":"OG002","value":"4.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"4.0","spread":"0.2"},{"groupId":"OG002","value":"4.0","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"4.0","spread":"0.3"},{"groupId":"OG002","value":"4.0","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"4.0","spread":"0.3"},{"groupId":"OG002","value":"4.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"0.4"},{"groupId":"OG001","value":"4.0","spread":"0.1"},{"groupId":"OG002","value":"4.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"0.5"},{"groupId":"OG001","value":"4.0","spread":"0.2"},{"groupId":"OG002","value":"4.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"0.5"},{"groupId":"OG001","value":"4.0","spread":"0.2"},{"groupId":"OG002","value":"4.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"0.5"},{"groupId":"OG001","value":"4.0","spread":"0.2"},{"groupId":"OG002","value":"4.0","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"0.5"},{"groupId":"OG001","value":"4.0","spread":"0.2"},{"groupId":"OG002","value":"4.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"0.5"},{"groupId":"OG001","value":"4.0","spread":"0.2"},{"groupId":"OG002","value":"4.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"0.4"},{"groupId":"OG001","value":"4.0","spread":"0.2"},{"groupId":"OG002","value":"4.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"0.4"},{"groupId":"OG001","value":"4.0","spread":"0.3"},{"groupId":"OG002","value":"4.0","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"0.3"},{"groupId":"OG001","value":"4.0","spread":"0.4"},{"groupId":"OG002","value":"4.0","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"0.3"},{"groupId":"OG001","value":"4.0","spread":"0.2"},{"groupId":"OG002","value":"4.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"0.4"},{"groupId":"OG001","value":"4.0","spread":"0.0"},{"groupId":"OG002","value":"4.0","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"0.4"},{"groupId":"OG001","value":"4.0","spread":"0.0"},{"groupId":"OG002","value":"4.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"0.4"},{"groupId":"OG001","value":"4.0","spread":"0.0"},{"groupId":"OG002","value":"4.0","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"0.5"},{"groupId":"OG001","value":"3.9","spread":"0.3"},{"groupId":"OG002","value":"4.1","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"CGI-BP-C: Depression (Treatment Period I)","description":"The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"0.8"},{"groupId":"OG001","value":"3.5","spread":"0.8"},{"groupId":"OG002","value":"3.5","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"1.0"},{"groupId":"OG001","value":"3.1","spread":"0.9"},{"groupId":"OG002","value":"3.2","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"1.2"},{"groupId":"OG001","value":"2.9","spread":"0.9"},{"groupId":"OG002","value":"3.0","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"1.3"},{"groupId":"OG001","value":"2.8","spread":"1.0"},{"groupId":"OG002","value":"2.9","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"1.3"},{"groupId":"OG001","value":"2.7","spread":"1.0"},{"groupId":"OG002","value":"2.8","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"1.4"},{"groupId":"OG001","value":"2.6","spread":"1.1"},{"groupId":"OG002","value":"2.8","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"CGI-BP-C: Depression (Combined Treatment Period I and II)","description":"The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score. Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"3.5","spread":"0.8"},{"groupId":"OG002","value":"3.5","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"3.1","spread":"0.9"},{"groupId":"OG002","value":"3.1","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"2.9","spread":"0.9"},{"groupId":"OG002","value":"2.9","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"2.7","spread":"1.0"},{"groupId":"OG002","value":"2.7","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"2.6","spread":"1.0"},{"groupId":"OG002","value":"2.7","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"2.5","spread":"1.1"},{"groupId":"OG002","value":"2.5","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"2.5","spread":"1.1"},{"groupId":"OG002","value":"2.4","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"1.2"},{"groupId":"OG001","value":"2.6","spread":"1.2"},{"groupId":"OG002","value":"2.4","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"1.2"},{"groupId":"OG001","value":"2.6","spread":"1.2"},{"groupId":"OG002","value":"2.4","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"1.2"},{"groupId":"OG001","value":"2.4","spread":"1.0"},{"groupId":"OG002","value":"2.4","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"1.2"},{"groupId":"OG001","value":"2.5","spread":"1.3"},{"groupId":"OG002","value":"2.2","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"1.0"},{"groupId":"OG001","value":"2.3","spread":"1.2"},{"groupId":"OG002","value":"2.2","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"0.9"},{"groupId":"OG001","value":"2.1","spread":"1.1"},{"groupId":"OG002","value":"2.2","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"0.9"},{"groupId":"OG001","value":"1.9","spread":"0.9"},{"groupId":"OG002","value":"2.2","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"1.0"},{"groupId":"OG001","value":"2.0","spread":"1.2"},{"groupId":"OG002","value":"2.1","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"1.0"},{"groupId":"OG001","value":"1.8","spread":"0.9"},{"groupId":"OG002","value":"2.1","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"1.0"},{"groupId":"OG001","value":"1.8","spread":"0.8"},{"groupId":"OG002","value":"2.1","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"0.9"},{"groupId":"OG001","value":"2.0","spread":"1.0"},{"groupId":"OG002","value":"1.9","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"1.0"},{"groupId":"OG001","value":"1.9","spread":"0.9"},{"groupId":"OG002","value":"1.9","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"1.0"},{"groupId":"OG001","value":"1.7","spread":"0.9"},{"groupId":"OG002","value":"1.8","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"1.2"},{"groupId":"OG001","value":"2.5","spread":"1.4"},{"groupId":"OG002","value":"2.6","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"CGI-BP-C: Overall Bipolar Illness (Treatment Period I)","description":"The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"0.8"},{"groupId":"OG001","value":"3.5","spread":"0.8"},{"groupId":"OG002","value":"3.5","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"1.0"},{"groupId":"OG001","value":"3.1","spread":"0.9"},{"groupId":"OG002","value":"3.2","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"1.2"},{"groupId":"OG001","value":"2.9","spread":"0.9"},{"groupId":"OG002","value":"3.0","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"1.3"},{"groupId":"OG001","value":"2.8","spread":"1.0"},{"groupId":"OG002","value":"2.9","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"1.4"},{"groupId":"OG001","value":"2.7","spread":"1.0"},{"groupId":"OG002","value":"2.9","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"1.5"},{"groupId":"OG001","value":"2.6","spread":"1.1"},{"groupId":"OG002","value":"2.8","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"CGI-BP-C: Overall Bipolar Illness (Combined Treatment Period I and II)","description":"The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score. Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"3.5","spread":"0.8"},{"groupId":"OG002","value":"3.5","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"3.1","spread":"0.9"},{"groupId":"OG002","value":"3.2","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"2.9","spread":"0.9"},{"groupId":"OG002","value":"2.9","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"2.7","spread":"1.0"},{"groupId":"OG002","value":"2.7","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"2.6","spread":"1.1"},{"groupId":"OG002","value":"2.7","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"2.5","spread":"1.1"},{"groupId":"OG002","value":"2.5","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"2.5","spread":"1.1"},{"groupId":"OG002","value":"2.4","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"1.2"},{"groupId":"OG001","value":"2.6","spread":"1.2"},{"groupId":"OG002","value":"2.4","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"1.2"},{"groupId":"OG001","value":"2.6","spread":"1.2"},{"groupId":"OG002","value":"2.4","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"1.2"},{"groupId":"OG001","value":"2.4","spread":"1.0"},{"groupId":"OG002","value":"2.4","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"1.1"},{"groupId":"OG001","value":"2.5","spread":"1.3"},{"groupId":"OG002","value":"2.2","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"1.0"},{"groupId":"OG001","value":"2.3","spread":"1.2"},{"groupId":"OG002","value":"2.3","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"0.9"},{"groupId":"OG001","value":"2.1","spread":"1.1"},{"groupId":"OG002","value":"2.2","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"0.9"},{"groupId":"OG001","value":"1.9","spread":"0.9"},{"groupId":"OG002","value":"2.2","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"1.1"},{"groupId":"OG001","value":"2.1","spread":"1.2"},{"groupId":"OG002","value":"2.2","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"1.0"},{"groupId":"OG001","value":"1.9","spread":"1.1"},{"groupId":"OG002","value":"2.1","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"1.0"},{"groupId":"OG001","value":"1.8","spread":"0.8"},{"groupId":"OG002","value":"2.1","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"0.9"},{"groupId":"OG001","value":"2.0","spread":"1.0"},{"groupId":"OG002","value":"1.9","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"1.0"},{"groupId":"OG001","value":"1.9","spread":"1.0"},{"groupId":"OG002","value":"2.0","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"1.0"},{"groupId":"OG001","value":"1.7","spread":"0.9"},{"groupId":"OG002","value":"1.8","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"1.2"},{"groupId":"OG001","value":"2.5","spread":"1.4"},{"groupId":"OG002","value":"2.7","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (Treatment Period I)","description":"An adverse event (AE) is defined as any undesirable or unintended sign (including abnormal laboratory test values), symptom, or disease occurring while the study drug was administered, regardless of whether or not there was a causal relationship with the study drug. A serious AE is defined as a an event resulting in death, persistent or significant disability/incapacity or congenital anomaly or birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"149","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"133","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (Combined Treatment Period I and II)","description":"An AE is defined as any undesirable or unintended sign (including abnormal laboratory test values), symptom, or disease occurring while the study drug was administered, regardless of whether or not there was a causal relationship with the study drug. A serious AE is defined as a an event resulting in death, persistent or significant disability/incapacity or congenital anomaly or birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important. AEs reported are AEs that occurred after the start of the FK949E treatment for all groups.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"63","spread":null},{"groupId":"OG002","value":"171","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"60","spread":null},{"groupId":"OG002","value":"159","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"39","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS): Total Score (Treatment Period I)","description":"The DIEPSS is a scale used to evaluate drug-induced extrapyramidal symptoms. DIEPSS is composed of 8 individual symptom parameters and a global assessment of severity, each rated on a 5-point scale, with lower scores indicating as \"normal.\" The DIEPSS total score ranges from 0 (none, normal) to 32 (severe), and excludes the global assessment of severity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.5"},{"groupId":"OG001","value":"0.0","spread":"0.7"},{"groupId":"OG002","value":"0.2","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.5"},{"groupId":"OG001","value":"0.0","spread":"0.7"},{"groupId":"OG002","value":"0.1","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.6"},{"groupId":"OG001","value":"0.0","spread":"0.8"},{"groupId":"OG002","value":"0.1","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in DIEPSS: Total Score (Combined Treatment Period I and II)","description":"The DIEPSS is a scale used to evaluate drug-induced extrapyramidal symptoms. DIEPSS is composed of 8 individual symptom parameters and a global assessment of severity, each rated on a 5-point scale, with lower scores indicating as \"normal.\" The DIEPSS total score ranges from 0 (none, normal) to 32 (severe), and excludes the global assessment of severity. Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"0.7"},{"groupId":"OG002","value":"0.2","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"0.7"},{"groupId":"OG002","value":"0.1","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.1","spread":"0.8"},{"groupId":"OG002","value":"0.1","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.9"},{"groupId":"OG001","value":"0.1","spread":"0.7"},{"groupId":"OG002","value":"0.1","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.8"},{"groupId":"OG001","value":"0.1","spread":"1.0"},{"groupId":"OG002","value":"0.1","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.7"},{"groupId":"OG001","value":"-0.0","spread":"0.6"},{"groupId":"OG002","value":"0.0","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.7"},{"groupId":"OG001","value":"0.0","spread":"0.7"},{"groupId":"OG002","value":"-0.1","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.4"},{"groupId":"OG001","value":"-0.0","spread":"0.6"},{"groupId":"OG002","value":"-0.1","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.5"},{"groupId":"OG001","value":"0.0","spread":"0.6"},{"groupId":"OG002","value":"-0.2","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.7"},{"groupId":"OG001","value":"-0.0","spread":"0.7"},{"groupId":"OG002","value":"0.0","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in DIEPSS: Parkinsonism (Treatment Period I)","description":"The DIEPSS is a scale used to evaluate drug-induced extrapyramidal symptoms. DIEPSS is composed of 8 individual symptom parameters and a global assessment of severity, each rated on a 5-point scale, with lower scores indicating as \"normal.\" Parkinsonism is a total of the gait disturbance, bradykinesia, salivation, muscle rigidity, and tremor scores and ranges from 0 (none, normal) to 20 (severe).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.4"},{"groupId":"OG001","value":"-0.1","spread":"0.5"},{"groupId":"OG002","value":"0.0","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.3"},{"groupId":"OG001","value":"-0.1","spread":"0.5"},{"groupId":"OG002","value":"-0.1","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.4"},{"groupId":"OG001","value":"-0.1","spread":"0.5"},{"groupId":"OG002","value":"-0.1","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in DIEPSS: Parkinsonism (Combined Treatment Period I and II)","description":"The DIEPSS is a scale used to evaluate drug-induced extrapyramidal symptoms. DIEPSS is composed of 8 individual symptom parameters and a global assessment of severity, each rated on a 5-point scale, with lower scores indicating as \"normal.\" Parkinsonism is a total of the gait disturbance, bradykinesia, salivation, muscle rigidity, and tremor scores and ranges from 0 (none, normal) to 20 (severe). Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"-0.1","spread":"0.5"},{"groupId":"OG002","value":"0.0","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-0.1","spread":"0.5"},{"groupId":"OG002","value":"-0.1","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"0.7"},{"groupId":"OG002","value":"-0.1","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.7"},{"groupId":"OG001","value":"-0.0","spread":"0.6"},{"groupId":"OG002","value":"-0.1","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.4"},{"groupId":"OG001","value":"-0.0","spread":"0.7"},{"groupId":"OG002","value":"-0.1","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.3"},{"groupId":"OG001","value":"-0.1","spread":"0.5"},{"groupId":"OG002","value":"-0.1","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.3"},{"groupId":"OG001","value":"-0.1","spread":"0.5"},{"groupId":"OG002","value":"-0.1","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.2"},{"groupId":"OG001","value":"-0.1","spread":"0.4"},{"groupId":"OG002","value":"-0.1","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.3"},{"groupId":"OG001","value":"-0.1","spread":"0.4"},{"groupId":"OG002","value":"-0.2","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.4"},{"groupId":"OG001","value":"-0.1","spread":"0.5"},{"groupId":"OG002","value":"-0.1","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Young Mania Rating Scale (YMRS) (Treatment Period I)","description":"The YMRS is a scale used to evaluate manic symptoms. The YMRS total score was the total assessment of assessed points for 11 items, ranges from 0 to 60 (each item is scored from either 0-4 or 0-8 by severity (0 = absent and 4/8 = displays mood/behavior to a greater degree). A lower score indicates \"Absent\" or \"Normal.\"","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.6"},{"groupId":"OG001","value":"-0.6","spread":"1.8"},{"groupId":"OG002","value":"-0.6","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.4"},{"groupId":"OG001","value":"-1.0","spread":"1.5"},{"groupId":"OG002","value":"-0.7","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.9"},{"groupId":"OG001","value":"-1.2","spread":"1.7"},{"groupId":"OG002","value":"-0.7","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.7"},{"groupId":"OG001","value":"-1.3","spread":"2.0"},{"groupId":"OG002","value":"-0.9","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"2.2"},{"groupId":"OG001","value":"-1.4","spread":"2.1"},{"groupId":"OG002","value":"-0.8","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.6"},{"groupId":"OG001","value":"-1.7","spread":"2.3"},{"groupId":"OG002","value":"-0.9","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"2.1"},{"groupId":"OG001","value":"-1.6","spread":"2.3"},{"groupId":"OG002","value":"-0.8","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in YMRS (Combined Treatment Period I and II)","description":"The YMRS is a scale used to evaluate manic symptoms. The YMRS total score was the total assessment of assessed points for 11 items, ranges from 0 to 60 (each item is scored from either 0-4 or 0-8 by severity (0 = absent and 4/8 = displays mood/behavior to a greater degree). A lower score indicates \"Absent\" or \"Normal.\" Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"-0.6","spread":"1.8"},{"groupId":"OG002","value":"-0.6","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-1.0","spread":"1.5"},{"groupId":"OG002","value":"-0.7","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-1.2","spread":"1.7"},{"groupId":"OG002","value":"-0.7","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-1.3","spread":"2.0"},{"groupId":"OG002","value":"-0.9","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-1.4","spread":"2.1"},{"groupId":"OG002","value":"-0.8","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-1.7","spread":"2.3"},{"groupId":"OG002","value":"-0.9","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-1.6","spread":"2.1"},{"groupId":"OG002","value":"-0.8","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-1.2","spread":"1.6"},{"groupId":"OG002","value":"-1.0","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.5"},{"groupId":"OG001","value":"-1.3","spread":"1.6"},{"groupId":"OG002","value":"-1.1","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.7"},{"groupId":"OG001","value":"-1.6","spread":"1.9"},{"groupId":"OG002","value":"-1.1","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"1.8"},{"groupId":"OG001","value":"-1.3","spread":"2.1"},{"groupId":"OG002","value":"-0.9","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"1.9"},{"groupId":"OG001","value":"-1.6","spread":"2.0"},{"groupId":"OG002","value":"-1.1","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"1.8"},{"groupId":"OG001","value":"-1.5","spread":"2.2"},{"groupId":"OG002","value":"-0.9","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.9"},{"groupId":"OG001","value":"-1.4","spread":"1.9"},{"groupId":"OG002","value":"-0.9","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"1.9"},{"groupId":"OG001","value":"-1.6","spread":"2.0"},{"groupId":"OG002","value":"-1.1","spread":"2.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"1.6"},{"groupId":"OG001","value":"-1.4","spread":"2.4"},{"groupId":"OG002","value":"-0.3","spread":"5.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"1.9"},{"groupId":"OG001","value":"-1.3","spread":"2.4"},{"groupId":"OG002","value":"-0.9","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.8"},{"groupId":"OG001","value":"-1.6","spread":"2.1"},{"groupId":"OG002","value":"-1.0","spread":"2.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.0"},{"groupId":"OG001","value":"-1.7","spread":"1.9"},{"groupId":"OG002","value":"-1.1","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"1.7"},{"groupId":"OG001","value":"-1.9","spread":"2.1"},{"groupId":"OG002","value":"-1.3","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.8"},{"groupId":"OG001","value":"-1.9","spread":"2.0"},{"groupId":"OG002","value":"-1.2","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.2"},{"groupId":"OG001","value":"-1.6","spread":"2.0"},{"groupId":"OG002","value":"-0.4","spread":"4.2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an Affirmative Response to Columbia Suicide Severity Rating Scale (C-SSRS): Suicidal Ideation (Treatment Period I)","description":"The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 5 items for suicide ideation (1. Wish to be dead; 2. Suicidal thoughts; 3. Suicidal thoughts with a method (no specific plan or intent to act); 4. Suicidal intent (without a specific plan); 5. Suicidal intent with specific plan. If participants responded with a negative response for questions 1 and 2, the remaining questions are skipped. If question 2 was responded to with a positive response, the remaining questions need to be asked.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Wish to be Dead (Combined Treatment Period I and II)","description":"The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 5 items for suicide ideation (1. Wish to be dead; 2. Suicidal thoughts; 3. Suicidal thoughts with a method (no specific plan or intent to act); 4. Suicidal intent (without a specific plan); 5. Suicidal intent with specific plan. If participants responded with a negative response for questions 1 and 2, the remaining questions are skipped. If question 2 was responded to with a positive response, the remaining questions need to be asked. Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Thoughts (Combined Treatment Period I and II)","description":"The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 5 items for suicide ideation (1. Wish to be dead; 2. Suicidal thoughts; 3. Suicidal thoughts with a method (no specific plan or intent to act); 4. Suicidal intent (without a specific plan); 5. Suicidal intent with specific plan. If participants responded with a negative response for questions 1 and 2, the remaining questions are skipped. If question 2 was responded to with a positive response, the remaining questions need to be asked. Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Thoughts With Method (Combined Treatment Period I and II)","description":"The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 5 items for suicide ideation (1. Wish to be dead; 2. Suicidal thoughts; 3. Suicidal thoughts with a method (no specific plan or intent to act); 4. Suicidal intent (without a specific plan); 5. Suicidal intent with specific plan. If participants responded with a negative response for questions 1 and 2, the remaining questions are skipped. If question 2 was responded to with a positive response, the remaining questions need to be asked. Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Intent Without a Plan (Combined Treatment Period I and II)","description":"The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 5 items for suicide ideation (1. Wish to be dead; 2. Suicidal thoughts; 3. Suicidal thoughts with a method (no specific plan or intent to act); 4. Suicidal intent (without a specific plan); 5. Suicidal intent with specific plan. If participants responded with a negative response for questions 1 and 2, the remaining questions are skipped. If question 2 was responded to with a positive response, the remaining questions need to be asked. Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Intent With a Plan (Combined Treatment Period I and II)","description":"The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 5 items for suicide ideation (1. Wish to be dead; 2. Suicidal thoughts; 3. Suicidal thoughts with a method (no specific plan or intent to act); 4. Suicidal intent (without a specific plan); 5. Suicidal intent with specific plan. If participants responded with a negative response for questions 1 and 2, the remaining questions are skipped. If question 2 was responded to with a positive response, the remaining questions need to be asked. Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors (Treatment Period I)","description":"The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 7 items to suicidal behaviors (1. suicide attempt; 2. Self-injury without suicide intent; 3. discontinued suicide attempt; 4. interrupted suicide attempt; 5. preliminary action to suicide; 6. suicidal behavior; 7. completed suicide).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Suicide Attempt (Combined Treatment Period I and II)","description":"The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 7 items to suicidal behaviors (1. suicide attempt; 2. Self-injury without suicide intent; 3. discontinued suicide attempt; 4. interrupted suicide attempt; 5. preliminary action to suicide; 6. suicidal behavior; 7. completed suicide). Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Self-injury Behavior Without Intent (Combined Treatment Period I and II)","description":"The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 7 items to suicidal behaviors (1. suicide attempt; 2. Self-injury without suicide intent; 3. discontinued suicide attempt; 4. interrupted suicide attempt; 5. preliminary action to suicide; 6. suicidal behavior; 7. completed suicide). Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Discontinued Attempt (Combined Treatment Period I and II)","description":"The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 7 items to suicidal behaviors (1. suicide attempt; 2. Self-injury without suicide intent; 3. discontinued suicide attempt; 4. interrupted suicide attempt; 5. preliminary action to suicide; 6. suicidal behavior; 7. completed suicide). Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Interrupted Attempt (Combined Treatment Period I and II)","description":"The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 7 items to suicidal behaviors (1. suicide attempt; 2. Self-injury without suicide intent; 3. discontinued suicide attempt; 4. interrupted suicide attempt; 5. preliminary action to suicide; 6. suicidal behavior; 7. completed suicide). Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Preliminary Act to Suicide (Combined Treatment Period I and II","description":"The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 7 items to suicidal behaviors (1. suicide attempt; 2. Self-injury without suicide intent; 3. discontinued suicide attempt; 4. interrupted suicide attempt; 5. preliminary action to suicide; 6. suicidal behavior; 7. completed suicide). Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Suicidal Behavior (Combined Treatment Period I and II)","description":"The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 7 items to suicidal behaviors (1. suicide attempt; 2. Self-injury without suicide intent; 3. discontinued suicide attempt; 4. interrupted suicide attempt; 5. preliminary action to suicide; 6. suicidal behavior; 7. completed suicide). Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Completed Suicide (Combined Treatment Period I and II)","description":"The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 7 items to suicidal behaviors (1. suicide attempt; 2. Self-injury without suicide intent; 3. discontinued suicide attempt; 4. interrupted suicide attempt; 5. preliminary action to suicide; 6. suicidal behavior; 7. completed suicide). Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":177},"commonTop":["Somnolence","Nasopharyngitis","Thirst","Constipation","Akathisia"]}}}